Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia

References

• HallekM. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–1287. doi:10.1002/ajh.2559531364186
   PubMed Web of Science ®Google Scholar
• HallekM, FischerK, Fingerle-RowsonG, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (London, England). 2010;376(9747):1164–1174. doi:10.1016/S0140-6736(10)61381-5
   PubMed Web of Science ®Google Scholar
• KeatingMJ, O’BrienS, AlbitarM, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–4088. doi:10.1200/JCO.2005.12.05115767648
   PubMed Web of Science ®Google Scholar
• FischerK, CramerP, BuschR, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29(26):3559–3566. doi:10.1200/JCO.2010.33.806121844497
   PubMed Web of Science ®Google Scholar
• FischerK, CramerP, BuschR, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30(26):3209–3216. doi:10.1200/JCO.2011.39.268822869884
   PubMed Web of Science ®Google Scholar
• ByrdJC, FurmanRR, CoutreSE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi:10.1056/NEJMoa121563723782158
   PubMed Web of Science ®Google Scholar
• YangW-C, ColletteY, NunèsJA, OliveD. Tec kinases: a family with multiple roles in immunity. Immunity. 2000;12(4):373–382. doi:10.1016/S1074-7613(00)80189-210795735
   PubMed Web of Science ®Google Scholar
• AranaE, HarwoodNE, BatistaFD. Regulation of integrin activation through the B-cell receptor. J Cell Sci. 2008;121(14):2279–2286. doi:10.1242/jcs.01790518596256
   PubMed Web of Science ®Google Scholar
• RhodesJ, MatoA, SharmanJP. Monitoring and management of toxicities of novel B cell signaling agents. Curr Oncol Rep. 2018;20(6):49. doi:10.1007/s11912-018-0694-x29644450
   PubMed Web of Science ®Google Scholar
• BurgerJA, ChiorazziN. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592–601. doi:10.1016/j.it.2013.07.00223928062
   PubMed Web of Science ®Google Scholar
• DimopoulosMA, TedeschiA, TrotmanJ, et al. Phase 3 trial of ibrutinib plus rituximab in waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410. doi:10.1056/NEJMoa180291729856685
   PubMed Web of Science ®Google Scholar
• NoyA, de VosS, ThieblemontC, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129(16):2224–2232. doi:10.1182/blood-2016-10-74734528167659
   PubMed Web of Science ®Google Scholar
• BurgerJA, TedeschiA, BarrPM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi:10.1056/NEJMoa150938826639149
   PubMed Web of Science ®Google Scholar
• ShanafeltTD, WangXV, KayNE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. doi:10.1056/NEJMoa181707331365801
   PubMed Web of Science ®Google Scholar
• WoyachJA, RuppertAS, HeeremaNA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. doi:10.1056/NEJMoa181283630501481
   PubMed Web of Science ®Google Scholar
• ByrdJC, BrownJR, O’BrienS, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223. doi:10.1056/NEJMoa140037624881631
   PubMed Web of Science ®Google Scholar
• O’BrienS, JonesJA, CoutreSE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–1418. doi:10.1016/S1470-2045(16)30212-127637985
   PubMed Web of Science ®Google Scholar
• WangML, BlumKA, MartinP, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745. doi:10.1182/blood-2015-03-63532626059948
   PubMed Web of Science ®Google Scholar
• MatoAR, NabhanC, ThompsonMC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874–879. doi:10.3324/haematol.2017.18290729419429
   PubMed Web of Science ®Google Scholar
• MatoAR, RoekerLE, AllanJN, et al. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018;93:1394–1401. doi:10.1002/ajh.2526130132965
   PubMed Web of Science ®Google Scholar
• BrownJR, MoslehiJ, O’BrienS, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–1805. doi:10.3324/haematol.2017.17104128751558
   PubMed Web of Science ®Google Scholar
• FarooquiM, ValdezJ, SotoS, BrayA, TianX, WiestnerA. Atrial fibrillation in CLL/SLL patients on ibrutinib. Blood. 2015;126(23):2933. doi:10.1182/blood.V126.23.2933.2933
   Google Scholar
• GuhaA, DerbalaMH, ZhaoQ, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72(6):697–698. doi:10.1016/j.jacc.2018.06.00230072003
   PubMed Web of Science ®Google Scholar
• CaronF, LeongDP, HillisC, FraserG, SiegalD. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772–778. doi:10.1182/bloodadvances.201600188329296721
   PubMed Web of Science ®Google Scholar
• LipskyAH, FarooquiMZ, TianX, et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015;100(12):1571–1578. doi:10.3324/haematol.2015.12667226430171
   PubMed Web of Science ®Google Scholar
• CaldeiraD, AlvesD, CostaJ, FerreiraJJ, PintoFJ, BenderR. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14(2):e0211228. doi:10.1371/journal.pone.021122830785921
   PubMed Web of Science ®Google Scholar
• RhodesJM, LoReVA, MatoAR, et al. Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes. Clin Lymphoma Myeloma Leuk. 2020;20(7):438–444.e431. doi:10.1016/j.clml.2020.02.00132197990
   PubMed Web of Science ®Google Scholar
• StephensDM, ByrdJC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133(12):1298–1307. doi:10.1182/blood-2018-11-84680830642919
   PubMed Web of Science ®Google Scholar
• GuoY, LiuY, HuN, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton’s tyrosine kinase. J Med Chem. 2019;62(17):7923–7940. doi:10.1021/acs.jmedchem.9b0068731381333
   PubMed Web of Science ®Google Scholar
• HarringtonBK, GulrajaniM, CoveyT, et al. ACP-196 is a second generation inhibitor of Bruton Tyrosine Kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908. doi:10.1182/blood.V126.23.2908.2908
   Web of Science ®Google Scholar
• SharmanJP, EgyedM, JurczakW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. doi:10.1016/S0140-6736(20)30262-232305093
   PubMed Web of Science ®Google Scholar
• GhiaP, PlutaA, WachM, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–2861. doi:10.1200/JCO.19.0335532459600
   PubMed Web of Science ®Google Scholar
• SongY, ZhouK, ZouD, et al. Treatment of patients with relapsed or refractory mantle–cell lymphoma with zanubrutinib, a selective inhibitor of bruton’s tyrosine kinase. Clin Cancer Res. 2020;26(16):4216–4224. doi:10.1158/1078-0432.CCR-19-370332461234
   PubMed Web of Science ®Google Scholar
• TamCS, TrotmanJ, OpatS, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–859. doi:10.1182/blood.201900116031340982
   PubMed Web of Science ®Google Scholar
• OuYC, PrestonRA, MarburyTC, et al. A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment. Leuk Lymphoma. 2020;1–9.
   Web of Science ®Google Scholar
• XuW, YangS, ZhouK, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13(1):48. doi:10.1186/s13045-020-00884-432393328
   PubMed Web of Science ®Google Scholar
• TamCS, RobakT, GhiaP, et al. Efficacy and safety of zanubrutinib in patients with treatment-naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): initial results from arm C of the sequoia (BGB-3111-304) trial. Blood. 2019;134(Supplement_1):499. doi:10.1182/blood-2019-125394
   Web of Science ®Google Scholar
• TamCS, RobakT, GhiaP, et al. Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. Haematologica. 2020. doi:10.3324/haematol.2020.259432
   Web of Science ®Google Scholar
• BrownJR, RobakT, GhiaP, et al. Efficacy and safety of zanubrutinib in patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial. Blood. 2020;136(Supplement 1):11–12. doi:10.1182/blood-2020-13428032276273
   PubMed Web of Science ®Google Scholar
• TamCS, FlinnIW, TedeschiA, et al. Zanubrutinib in combination with venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma and del(17p): arm D of the SEQUOIA (BGB-3111-304) trial. Blood. 2020;136(Supplement 1):24–25. doi:10.1182/blood-2020-13417932430494
   PubMed Web of Science ®Google Scholar
• MorenoC, GreilR, DemirkanF, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi:10.1016/S1470-2045(18)30788-530522969
   PubMed Web of Science ®Google Scholar
• FischerK, Al-SawafO, BahloJ, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa181528131166681
   PubMed Web of Science ®Google Scholar
• GoedeV, FischerK, BuschR, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110. doi:10.1056/NEJMoa131398424401022
   PubMed Web of Science ®Google Scholar
• TamCS, QuachH, NicolA, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4(19):4802–4811. doi:10.1182/bloodadvances.202000218333022066
   PubMed Web of Science ®Google Scholar
• SoumeraiJD, MatoAR, CarterJ, et al. Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax. J Clin Oncol. 2020;38(15_suppl):8006. doi:10.1200/JCO.2020.38.15_suppl.8006
   Web of Science ®Google Scholar
• TamCS, OpatS, ZhuJ, et al. PS1159 pooled analysis of safety data from monotherapy studies of the bruton tyrosine kinase (Btk) inhibitor, zanubrutinib (BGB-3111), in B-cell malignancies. HemaSphere. 2019;3(S1):526. doi:10.1097/01.HS9.0000562920.26603.5b
   Google Scholar
• DobieG, KuririFA, OmarMMA, et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin alphaIIbbeta3 in mice and humans. Blood Adv. 2019;3(24):4298–4311. doi:10.1182/bloodadvances.201900064031869418
   PubMed Web of Science ®Google Scholar
• HillmenP, BrownJR, EichhorstBF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020;16(10):517–523. doi:10.2217/fon-2019-084432207333
   PubMed Web of Science ®Google Scholar
• KohrtHE, Sagiv-BarfiI, RafiqS, et al. Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity. Blood. 2014;123(12):1957–1960. doi:10.1182/blood-2014-01-54786924652965
   PubMed Web of Science ®Google Scholar
• FlinsenbergTWH, TromedjoCC, HuN, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica. 2020;105(2):e76–e79. doi:10.3324/haematol.2019.22059031171645
   PubMed Web of Science ®Google Scholar
• JonesJA, MatoAR, WierdaWG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75. doi:10.1016/S1470-2045(17)30909-929246803
   PubMed Web of Science ®Google Scholar
• MatoAR, HillBT, LamannaN, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi-center study of 683 patients. Ann Oncol. 2017;28:1050–1056. doi:10.1093/annonc/mdx03128453705
   PubMed Web of Science ®Google Scholar
• WoysachJA, RuppertAS, GuinnD, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443. doi:10.1200/JCO.2016.70.228228418267
   PubMed Web of Science ®Google Scholar
• ShadmanM, SharmanJP, LevyMY, et al. Phase 2 study of zanubrutinib in patients with relapsed/refractory B-cell malignancies intolerant to ibrutinib/acalabrutinib. Blood. 2020;136(Supplement 1):51–52. doi:10.1182/blood-2020-134621
   Web of Science ®Google Scholar